Introduction {#section5-2049936119838228}
============

In the mid-1990s, combined antiretroviral treatment (cART) was a real revolution in the improvement of overall survival of HIV patients. Moreover, the prevalence of the more severe form of HIV-associated neurocognitive disorder (HAND), has been reduced to 5%.^[@bibr1-2049936119838228]^ Although the widespread use of cART has led to a marked decrease in the number of patients with more severe manifestations of HAND (e.g. HIV-associated dementia), less severe forms of HAND, namely asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), remain high in the cART era (between 33 and 60% of all HAND).^[@bibr2-2049936119838228],[@bibr3-2049936119838228]^ Longitudinal cohort studies showed that ANI, even with a suppressed plasma viral load, evolved into symptomatic cognitive impairment. This spectrum of mild HAND impacts on daily functioning, poor adherence and mortality as occurring earlier during the course of HIV infection.^[@bibr4-2049936119838228][@bibr5-2049936119838228]--[@bibr6-2049936119838228]^

The most common causes of this change, in proportion rather than an actual crude increase in the number of individuals diagnosed, include: (a) incomplete penetration of antiretroviral drugs (ARVs) into the central nervous system (CNS) with consequent deficient viral suppression, (b) drug-resistant viruses in the CNS, (c) neuronal damage due to perpetual viral replication in the CNS, (d) neurotoxic cART exposure as well as to other factors that impair cognition.^[@bibr3-2049936119838228]^

Cerebrospinal fluid (CSF) and plasma are thought to reflect the neuropathology with a complex protein profile comprised of different cell types. Prior to the introduction of cART, factors associated with HAND included plasma and CSF HIV RNA and inflammation markers \[e.g. chemokine (CC motif) ligand 2 (CCL2), tumor necrosis factor (TNF), interleukin (IL)-6, and neopterin\]. The complex nature of factors contributing to HAND suggests these disorders reflect different pathophysiological mechanisms. There is an obvious need for markers that reflect HAND in all of its complexity.

Previous reviews on the topic focused on the current knowledge of HAND pathogenesis and several markers (fluid and neuroimaging).^[@bibr7-2049936119838228][@bibr8-2049936119838228]--[@bibr9-2049936119838228]^ However, it is unclear whether these markers can distinguish among various stages of HAND. The purpose of this review is to assess whether previous studies actually address the question of an optimal management of HAND by examine the evolving concepts of HAND neuropathogenesis, and new treatment approaches. Our focus was to evaluate studies of adjunctive therapies and fluid markers of neurological injury/immune activation in order to evaluate a closer relationship between early involvement and the onset of cognitive decline. Finally, we discussed future perspectives in the field of HAND therapies and proposed recommendations to improve quality and efficiency of clinical trials for optimal pharmacological management of HAND.

Methods {#section6-2049936119838228}
=======

A literature search was performed in *PubMed* to identify studies published between January 1996 and October 2018 using terms as 'HIV-associated neurocognitive disorder', 'HAND', mild neurocognitive disorder MND 'asymptomatic neurocognitive impairment ANI', 'adjuvant therapies', 'antiretroviral treatment cART', 'neurotoxicity', 'injury cART intensification', 'protease inhibitors', 'nonnucleoside reverse transcriptase inhibitor', 'nucleoside reverse transcriptase inhibitors', 'integrase strand transfer inhibitors', 'fluid markers', and 'cerebrospinal fluid'. Additionally, the reference list of each article was searched manually to include pertinent citations. Inclusion criteria were: adult human patients, publication date, and the English language. Letters, summaries, dissertations, reviews, theses, animal models and case reports were excluded.

To be eligible, studies had to meet the following conditions: (1) population: participants in the trials had to meet diagnostic criteria of HAND, ANI and MND and (2) primary outcomes were: new approaches to the treatment of HAND and their implications in the era of HIV eradication, specifically, adjunctive therapies targeting CNS inflammation and other metabolic processes, potential neuronal biomarkers for HAND; secondary outcomes were: evolving concepts of HAND neuropathogenesis.

Study selection and data extraction {#section7-2049936119838228}
-----------------------------------

A total of three investigators with advanced training in HAND pharmacotherapy and critical appraisal screened all titles and abstracts retrieved through the search. We further examined all full-text articles of identified abstracts that met inclusion criteria. In case of debate during the eligibility assessment, the other two study investigator reviewed the abstract/full text in doubt and made a final objective approval. We only included studies that fulfilled the appropriate diagnostic criteria established by the original authors. Any discrepancies between the investigators were resolved through discussion.

The variables extracted from each manuscript were the following: study type (including design), sample characteristics, type of treatment, dosage/mechanism of action, neuropsychological/biochemical/functional measures and main outcomes. After retrieving the full text of included studies, all investigators independently assessed the methodological quality of randomized controlled trials (RCTs) studies according to the *Cochrane Handbook for Systematic Reviews of Interventions*,^[@bibr10-2049936119838228]^ and the Newcastle--Ottawa scale (NOS) for assessing the methodological quality of cross-sectional studies.^[@bibr11-2049936119838228]^ The Cochrane risk of bias tool for RCTs incorporates sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias.^[@bibr10-2049936119838228]^ Each item is rated as 'yes', 'no', or 'unclear'. The quality of clinical trials can be divided into three levels. If the study design satisfied all the preceding six criteria, it is considered as an A level, which means a low risk of bias. A B level is assigned if one or more criteria are partly met, and when one or more criteria are not met, the study was defined as a C level, implying a high risk of bias.^[@bibr10-2049936119838228]^ The NOS criteria comprised: (i) Patient selection (scores, 0--4); (ii) comparability of subjects (scores, 0--2); and (iii) clinical outcomes (scores, 0--3). The NOS scores ranged between 0 and 9 and a score ⩾7 indicated that a study was of good quality.^[@bibr11-2049936119838228]^

![Schematic Representation of HAND neuropathogenesis. A Schematic model demonstrating the key steps (activated macrophages, microglial cells) of HAND pathogenesis as well as potential targets of current therapies such as anti-inflammatory (minocycline), NMDAR antagonists/anti-excitotoxic (memantine), antioxidants agents (selegiline).\
HAND, HIV-associated neurocognitive disorder; NMDAR, -N-methyl-D-aspartate receptor.](10.1177_2049936119838228-fig1){#fig1-2049936119838228}

Results {#section8-2049936119838228}
=======

The described search identified 407 relevant studies ([Figure 1 supplementary material](https://journals.sagepub.com/doi/suppl/10.1177/2049936119838228)), of which 248 were excluded (duplicates, obvious irrelevance to our study aim by checking the titles and abstracts). A total of 159 abstracts were identified as relevant or potentially relevant. Of those, 122 were excluded (full texts could not be retrieved, eligibility criteria not met). Finally, 37 studies were reviewed as a full text. We performed qualitative data synthesis, organizing the results by cART (*n* = 11; [Table 1](#table1-2049936119838228){ref-type="table"}), adjuvant therapies (*n* = 12; [Table 2](#table2-2049936119838228){ref-type="table"}), and neuronal biomarkers (*n* = 12; [Table 3](#table3-2049936119838228){ref-type="table"}). No further relevant citations were found from weekly electronic database updates up to 1 October 2018. Finally, we analyzed 35 articles: 10 RCTs, 17 cross-sectional, 1 open-label, single arm, 1 prospective, 1 cohort, 1 transversal analysis, 1 placebo-controlled, 2 longitudinal, 1 population-based with a total of 7716 participants ([Tables 1](#table1-2049936119838228){ref-type="table"}[](#table2-2049936119838228){ref-type="table"}--[3](#table3-2049936119838228){ref-type="table"}). Given the heterogeneity of included studies, it was impossible to conduct meta-analyses. [Tables 1](#table1-2049936119838228){ref-type="table"}[](#table2-2049936119838228){ref-type="table"}--[3](#table3-2049936119838228){ref-type="table"} summarize the main methodological characteristics and results of the included studies. Our review identified 10 RCTs with a moderate methodological quality of level B. The NOS scores for cross-sectional studies ranged between 7 and 8 with good quality.

###### 

Summary of main characteristics of cART.

![](10.1177_2049936119838228-table1)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, y                                Study type                                                     Sample                                                                                                     TX, dosage/mechanism of action                                                                             NP/biochemical/functional measures                                                                                     Main outcomes                                                                                                                                        Quality level
  ---------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  Ferrando^[@bibr12-2049936119838228]^     Cross-sectional study                                          15 HIV homo-/bisexual men with CI under cART (CD4 count: 254)\                                             2 or \>NRTI with or without nevirapine or delavirdine (non-NRTI) with ritonavir, indinavir or nelfinavir   California verbal learning test\                                                                                       cART benefits\                                                                                                                                       7
                                                                                                          33 HIV homo-/bisexual men with CI without cART (CD4 count, mean: 342)                                                                                                                                                 SDMT\                                                                                                                  neuropsychological function through the reduction of viral load                                                                                      
                                                                                                                                                                                                                                                                                                                                Digit symbol test\                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                GP                                                                                                                                                                                                                                                                          

  Cohen^[@bibr13-2049936119838228]^        Longitudinal                                                   126 HIV-positive women\                                                                                    PI with NRTI and NNRTI or PI with NRTI                                                                     GP, CTM, COWAT,\                                                                                                       cART improved on verbal fluency, information processing and psychomotor speed                                                                        
                                                                                                          439 HIV-negative\                                                                                                                                                                                                     FWL                                                                                                                                                                                                                                                                         
                                                                                                          CD4 count mean (SD): 64.9 (44.7)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                          elevated plasma viral loads (HIV RNA77978 ± 81,644 copies/ml)                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Cysique^[@bibr14-2049936119838228]^      Prospective study                                              42 HIV patients under NeuroART\                                                                            NeuroART: composed of at least 3 neuroactive drugs\                                                        DASS, digit span, verbal memory, GP, trail-making test, symbol digit modalities test, Rey--Osterrieth complex figure   cART regimen was associated with neuropsychological\                                                                                                 
                                                                                                          58 HIV patients under cART\                                                                                cART: Ritonavir-PI combination                                                                                                                                                                                                    improvement                                                                                                                                          
                                                                                                          30 HIV-negative controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Giancola^[@bibr15-2049936119838228]^     cross-sectional study                                          107 HAND patients\                                                                                         PI + NNRTI + NRTI                                                                                          WAIS-R, digit span, trail-making B, Stroop color-word,\                                                                no significant improvement                                                                                                                           7
                                                                                                          +placebo group\                                                                                                                                                                                                       controlled oral word, Rey Auditory verbal learning,\                                                                                                                                                                                                                        
                                                                                                          Ages: 18--65 years\                                                                                                                                                                                                   Rey complex Figure delayed, and Babcock story, GP, Rey complex figure, copy                                                                                                                                                                                                 
                                                                                                          cART: stable regimen\                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                          CD4 count: not specified                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Marra^[@bibr16-2049936119838228]^        Multisite longitudinal observational study                     79 HIV patients with stable cART\                                                                          combination of NRTI and NNRTI                                                                              Concentration of HIV RNA in CSF and blood and neuropsychological test scores (NPZ4 and NPZ8)                           Antiretrovirals with good CPE were associated with poorer neurocognitive performance                                                                 
                                                                                                          CPE rank of at least 2 or less than 2                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Sactor^[@bibr17-2049936119838228]^       6 monthsCross- sectional                                       33 HIV humans with mild dementia (MSK stage 1)\                                                            Triommune (stavudine, lamivudine, and nevirapine)                                                          AVLT, SDMT, GP\                                                                                                        Cognitive impairment improved significantly on a test of executive function                                                                          
                                                                                                          7 HIV humans with moderate (MSK stage: 2)\                                                                                                                                                                            Color trails 1, 2                                                                                                                                                                                                                                                           
                                                                                                          cART: stable regimen\                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                          CD4 count, mean (SD): 129 (79.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Garvey^[@bibr18-2049936119838228]^       Cross- sectional                                               101 HIV patients with\                                                                                     NNRTI\                                                                                                     Composite speed score\                                                                                                 HIV disease status (lower nadir CD4+ count) and older age, but not CPE score or cART drug class, are associated with poorer cognitive performance.   7
                                                                                                          stable cART\                                                                                               PI                                                                                                         Composite accuracy score\                                                                                                                                                                                                                                                   
                                                                                                          plasma HIV RNA: \<50 copies/ml\                                                                                                                                                                                       Executive function score                                                                                                                                                                                                                                                    
                                                                                                          CD4+ count, mean: 525 cells/µl                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Smurzynski^[@bibr19-2049936119838228]^   Population study                                               2970 HIV patients\                                                                                         Combination of NRTI and NNRTI                                                                              Trail-making test, Part A and B; WAIS-R                                                                                May be associated with better neurocognitive functioning                                                                                             
                                                                                                          vRNA \< 50 copies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Kahouadji^[@bibr20-2049936119838228]^    Cross-sectional study                                          54 HIV patients with stable cART divided in 3 groups: (CPE ⩽ 1, CPE between 1.5 and 2.5, and CPE ⩾ 2.5)\   Combination of NRTI and NNRTI                                                                              FAB clock drawing test, 5 words test for memory and praxis (using the praxis ability scale                             cART with high CPE scores was associated with poorer executive performances                                                                          7
                                                                                                          CD4 count, mean (SD): 460.4 (192.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Ma^[@bibr21-2049936119838228]^           HIV Antiretroviral Therapy Effects Research (CHARTER) cohort   272 HIV humans with Efavirenz \[CD4 count, mean (SD): 499 (279)\]\                                         Efavirenz or lopinavir-ritonavir for at least 12 weeks                                                     Global functioning Verbal fluency Executive functioning\                                                               Efavirenz users had worse speed of information processing (*p =* 0.02) and executive functioning (*p =* 0.03) compared lopinavir-ritonavir.          
                                                                                                          173 HIV lopinavir-ritonavir\                                                                                                                                                                                          Speed of information                                                                                                                                                                                                                                                        
                                                                                                          \[ CD4 count, mean (SD): 443 (290)\]                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Falasca^[@bibr22-2049936119838228]^      Analytical transversal study                                   40 HIV patients under stable cART\                                                                         NRTI as backbone plus NNRTI in 20 patients, plus PI in 13 patients, and plus INI in seven patients         Rey word spiked\                                                                                                       cART-associated with poor neurocognitive outcome, especially in verbal fluency, fine motility, and Zung Depression Scale                             
                                                                                                          plasma viral load: \<40 copies HIV RNA/ml\                                                                                                                                                                            Stroop test E spiked\                                                                                                                                                                                                                                                       
                                                                                                          CD4+ count: \>300 cells/ml                                                                                                                                                                                            Trail-making test B---T, GP test DOM, verbal fluency test spiked, Zung depression score                                                                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AVLT, auditory verbal learning test; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitors; INSTI, integrase strand transfer inhibitors; SDMT, symbol digit modalities test; GP, grooved pegboard test; COWAT, controlled oral word generation; FWL, four-word learning words recalled; DASS, depression anxiety stress scale; FAB, frontal assessment battery; CNS penetration effectiveness; WAIS-R, Wechsler adult intelligence scale-revised.

###### 

Summary of main characteristics of adjuvant therapies.

![](10.1177_2049936119838228-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, year                                     Study type                                    Sample                                               TX, dosage/mechanism of action                                                                             NP/biochemical/functional measures                       Main outcomes                                                                                                                                Quality level
  ------------------------------------------------- --------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  **Clinical**                                      **Studies (n = 12)**                                                                                                                                                                                                                                                                                                                                                                                                

  The Dana Consortium^[@bibr23-2049936119838228]^   12 w RCT double-blind placebo                 30 HAND + placebo group\                             OPC-14117 240 mg/d/ lipophilic antioxidant\                                                                Rey auditory\                                            No significant NP improvement                                                                                                                B
                                                                                                  Ages: NS\                                            As scavenger superoxide anion radicals                                                                     Verbal learning test, digit symbol test, 2Cal Cap,\                                                                                                                                                   
                                                                                                  ART: stable regimen for ⩾6 weeks\                                                                                                                               GP\                                                                                                                                                                                                   
                                                                                                  CD4 count: NS\                                                                                                                                                  CD4 count (mean): 234 cells/mm^3^\                                                                                                                                                                    
                                                                                                  VL: NS                                                                                                                                                          CD4 nadir: NR\                                                                                                                                                                                        
                                                                                                                                                                                                                                                                  Plasma VL: NR                                                                                                                                                                                         

  The Dana Consortium^[@bibr24-2049936119838228]^   10 w RCT-double blind parallel\               36 HAND patients\                                    Deprenyl 2.5 mg /3×/w /monoamine oxidase B inhibitor\                                                      Rey auditory\                                            Deprenyl: significant improvement on tests of verbal memory\                                                                                 B
                                                    2 x 2 factorial design                        Ages: ⩾18 years\                                     thioctic acid 2.5 nig / 3×/w antioxidant                                                                   verbal learning test, digit symbol test, 2Cal Cap,\      thioctic acid: No significant NP improvement                                                                                                 
                                                                                                  ART: stable regimen\                                                                                                                                            GP\                                                                                                                                                                                                   
                                                                                                  for ⩾6 weeks\                                                                                                                                                   CD4 count (mean): 208 cells/mm^3^\                                                                                                                                                                    
                                                                                                  CD4 count: NS\                                                                                                                                                  CD4 nadir: NR\                                                                                                                                                                                        
                                                                                                  VL: NS                                                                                                                                                          Plasma VL: NR                                                                                                                                                                                         

  Heseltine^[@bibr25-2049936119838228]^             6 m RCT-double blind placebo                  205 HIV humans + placebo group with CI\              Peptide T intranasally of 2 mg/3×/d *versus* placebo                                                       AMNART, WAIS-R, C-W, NI-PI, WMS-R,\                      improvement NP in patients with NP global deficit score ⩾0.5 or with relatively preserved immunological status (CD4 count \> 0.200.10^9^/l   B
                                                                                                  Ages: 18--39 years\                                                                                                                                             CD4 count (mean): 208 cells/mm^3^\                                                                                                                                                                    
                                                                                                  ART: stable regimen for 12 w\                                                                                                                                   CD4 nadir: NR\                                                                                                                                                                                        
                                                                                                  CD4 count: NS\                                                                                                                                                  Plasma VL: NR                                                                                                                                                                                         
                                                                                                  VL: NS                                                                                                                                                                                                                                                                                                                                                                

  Schifitto^[@bibr26-2049936119838228]^             8 m RCT-double blind placebo                  30 HIV humans + placebo group with CI\               Lexipafant 250 mg/12 h/platelet-activating factor                                                          Rey auditory verbal learning test, digit symbol test,\   trends toward improvement NP, especially verbal memory                                                                                       B
                                                                                                  Ages: NS\                                                                                                                                                       GP\                                                                                                                                                                                                   
                                                                                                  ART: stable regimen for ⩾6 weeks\                                                                                                                               CD4 count (mean): 390 cells/mm^3^\                                                                                                                                                                    
                                                                                                  CD4 count: NS\                                                                                                                                                  CD4 nadir: NR\                                                                                                                                                                                        
                                                                                                  VL: NS                                                                                                                                                          Plasma VL: NR                                                                                                                                                                                         

  Clifford^[@bibr27-2049936119838228]^              10 w RCT-double blind                         64 HIV humans with motor + CI\                       CPI-1189/ TNFα blocker                                                                                     *CSF immune marker*: MCP-1 MIP-1α, p75, TNFII\           No significant motor or NP                                                                                                                   B
                                                                                                  Ages: not specified\                                                                                                                                            IL10, IL6, TNFα                                                                                                                                                                                       
                                                                                                  ART: stable regimen for ⩾8 weeks, if on ART\                                                                                                                                                                                                                                                                                                                          
                                                                                                  CD4 count: NS\                                                                                                                                                                                                                                                                                                                                                        
                                                                                                  VL: NS                                                                                                                                                                                                                                                                                                                                                                

  Schifitto^[@bibr28-2049936119838228]^             pilot 10w placebo-controlled                  22 HIV humans with (*n* = 16) without CI (*n* = 6)   VPA 250 mg /HDAC inhibitor                                                                                 CD4+\                                                    NAA/Cr increase\                                                                                                                             
                                                                                                                                                                                                                                                                  HIV RNA plasma\                                          improved NP                                                                                                                                  
                                                                                                                                                                                                                                                                  MRS and\                                                                                                                                                                                              
                                                                                                                                                                                                                                                                  DTI indices (NAA/Cr, Cho/Cr, MI/Cr)                                                                                                                                                                   

  Evans^[@bibr29-2049936119838228]^                 24 w RCT-double blind                         86 HIV humans CI\                                    Selegiline TS3 mg/d/ MAO-B inhibitor                                                                       CD4 count: NS                                            No significant NP                                                                                                                            B
                                                                                                  Ages: not specified                                                                                                                                                                                                                                                                                                                                                   

  Schifitto^[@bibr30-2049936119838228]^             16 w RCT double-blind                         140 HAND + ADC humans\                               Memantine/ NMDA antagonist                                                                                 NPZ8 scores\                                             No significant NP                                                                                                                            B
                                                                                                  Ages: not specified\                                                                                                                                            CD4 nadir: NR\                                                                                                                                                                                        
                                                                                                  ART: stable regimen\                                                                                                                                            Plasma VL (median): 112 copies/ml                                                                                                                                                                     
                                                                                                  CD4 count: not specified\                                                                                                                                                                                                                                                                                                                                             
                                                                                                  VL: not specified                                                                                                                                                                                                                                                                                                                                                     

  Schifitto^[@bibr31-2049936119838228]^             10 week single arm, open label                15 HIV humans with CI\                               Lithium 300 mg/ mood-stabilizing agent                                                                     CD4: NS\                                                 no significant NP                                                                                                                            \-
                                                                                                  Age: NS\                                                                                                                                                        VL: NS\                                                                                                                                                                                               
                                                                                                  ART: stable regimen for ⩾8 weeks\                                                                                                                               MRS, DTI                                                                                                                                                                                              
                                                                                                  CD4 count: NS\                                                                                                                                                                                                                                                                                                                                                        
                                                                                                  VL: NS                                                                                                                                                                                                                                                                                                                                                                

  Sacktor^[@bibr32-2049936119838228]^               24 w RCT-double blind                         107 HAND humans\                                     Minocycline 100 mg /12h/ tetracycline antibiotic                                                           NPZ-8b scores\                                           No significant NP improvement                                                                                                                B
                                                                                                  +placebo group\                                                                                                                                                 CD4 count (mean ± SD): 543 ± 283 cells/mm^3^\                                                                                                                                                         
                                                                                                  Ages: 18--65 years\                                                                                                                                             CD4 nadir (mean ± SD): 270 ± 254 cells/mm^3^\                                                                                                                                                         
                                                                                                  ART: stable regimen\                                                                                                                                            Plasma VL \<30 copies/ml (mean): 86%                                                                                                                                                                  
                                                                                                  CD4 count: not specified                                                                                                                                                                                                                                                                                                                                              

  Simioni^[@bibr33-2049936119838228]^               RCT-double blind-placebo                      17 aviremic HAND humans\                             Oral rivastigmine up to 12 mg/day for 20 weeks) followed by placebo (20 weeks)/ cholinesterase inhibitor   ADAS-Cog scale\                                          No significant NP improvement                                                                                                                B
                                                                                                  Age: NS\                                                                                                                                                        HDS\                                                                                                                                                                                                  
                                                                                                  ART: NS, but all enrolled on ART.\                                                                                                                              HAD-D\                                                                                                                                                                                                
                                                                                                  CD4 count: NS\                                                                                                                                                  HAD-A\                                                                                                                                                                                                
                                                                                                  VL: undetectable VL                                                                                                                                             MOS-HIV                                                                                                                                                                                               

  Letendre^[@bibr34-2049936119838228]^              12 w cross-sectional study (CHARTER cohort)   658 HIV humans with CI                               Trazodone, paroxetine, sertraline, venlafaxine, citalopram, escitalopram/SRIs\                             HIV RNA measurements in plasma and CSF\                  SRIs may reduce HIV replication in CSF and improve NP performance.\                                                                          
                                                                                                                                                       Atorvastatin Pravastatin\                                                                                  Rey auditory verbal memory\                              The same was not confirmed for statins                                                                                                       
                                                                                                                                                       Simvastatin Fluvastatin\                                                                                   Symbol digit\                                                                                                                                                                                         
                                                                                                                                                       Lovastatins/statins                                                                                        GP                                                                                                                                                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cal Cap, California Computerized Assessment Package; ADAS-Cog, Alzheimer's disease assessment scale-cognitive subscale; AMNART, American version of the Nelson adult reading test; ART, antiretroviral therapy; CI, cognitive impairment but not specified of which type of HAND; CSF, cerebrospinal fluid; C-W, color-word; DTI, diffusion tensor imaging; EPO, erythropoietin; FWM, frontal white matter; GP, grooved pegboard; h, hour; HAD-A, hospital anxiety scale; HAD-D, hospital depression scale; HAND, HIV-associated neurocognitive disorder; HDAC, Histone deacetylase; HDS, HIV dementia scale; IGF-I, insulin-like growth factor-I; IL, interleukin; m, months; MCP-1, monocyte chemoattractant protein-1; MIP-1alpha, macrophage inflammatory protein-1; MRS, magnetic resonance spectroscopy; NI-PI, name identity-physical identity; NMDA, N-methyl-d-aspartate; NP neuropsychiatric; NR, not reported; NS, not specified; RCT, randomized controlled trial; SRIs, serotonin reuptake inhibitors; TNFα, tumor necrosis factor α; TS, transdermal system; VL, viral load; VPA, valproic acid; w, weeks; WAIS-R, Wechsler adult intelligence scale-revised; WMS-R, Wechsler memory scale-revised.

###### 

Summary of main characteristics of fluid neuronal biomarkers.

![](10.1177_2049936119838228-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, year                                              Study type                      Sample                                                                                                                                                                                   Biomarker                                                                                                                                                                       NP measures                                                Main outcomes                                                                                                                                                                                                                                                                                                                                                         Total NOS/quality level
  ---------------------------------------------------------- ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  Sui and colleagues^[@bibr35-2049936119838228]^             Cross-sectional                 16 HAND\                                                                                                                                                                                 CSF + plasma sCD40L                                                                                                                                                             NR in details                                              A significantly higher level of sCD40L was detected in HAND respect NP normal                                                                                                                                                                                                                                                                                         8
                                                                                             9 HIV + NP normal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Gisslen and colleagues^[@bibr36-2049936119838228]^         Cross-sectional                 21 HAND\                                                                                                                                                                                 CSF Aβ42, Aβ40, t-tau, p-tau181\                                                                                                                                                NR in details                                              Parallel reductions of CSF sAPPα and sAPPβ in HAND and CNS opportunistic infections suggest an effect of CNS immune activation or inflammation on neuronal amyloid synthesis or processing. Elevation of CSF t-tau in some HAND and CNS infection patients without concomitant increase in p-tau indicates neural injury without preferential accumulation of p-tau   8
                                                                                             25 HIV + opportunistic infections\                                                                                                                                                       sAPPα, sAPPβ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                             64 HIV-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Clifford and colleagues 2009^[@bibr37-2049936119838228]^   Cross-sectional                 **Table 3. Summary of main characteristics of fluid neuronal biomarkers**\                                                                                                               CSF Aβ42, Aβ40, t-tau, p-tau181                                                                                                                                                 NR in details                                              CSF Aβ42 levels of HAND are similar to those in mild DAT.\                                                                                                                                                                                                                                                                                                            8
                                                                                             49 HAND\                                                                                                                                                                                                                                                                                                                                                                                                                            Normal or slightly depressed CSF tau and p-tau181 distinguish these patients with HAND from patients with DAT                                                                                                                                                                                                                                                         
                                                                                             68 DAT\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                             21 HIV + NP\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                             50 HIV + controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Hagderg and colleagues^[@bibr38-2049936119838228]^         Cross-sectional                 382 untreated HIV + NP\                                                                                                                                                                  Blood + CSF neopterin                                                                                                                                                           NR in details                                              Blood neopterin was also higher in the HAND patients, but did not show the same increase as CSF                                                                                                                                                                                                                                                                       8
                                                                                             73 untreated HAND\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                             233 treated HIV + NP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Burdo and colleagues^[@bibr39-2049936119838228]^           Cross-sectional                 15 HIV + (9 ANI-6 MND)\                                                                                                                                                                  sCD163in CSF and plasma                                                                                                                                                         NR in details                                              Elevated sCD163 in plasma but not CSF is a marker of HAND                                                                                                                                                                                                                                                                                                             8
                                                                                             19 HIV + NP normal\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                             34 HIV controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Williams and colleagues^[@bibr40-2049936119838228]^        12 w RCT double-blind placebo   60 HIV humans                                                                                                                                                                            CCR2 on CD14(+) CD16(+) in blood                                                                                                                                                MHBB battery                                               CCR2 was significantly increased on CD14+CD16+ monocytes in individuals with HAND compared to infected people with normal cognition                                                                                                                                                                                                                                   B

  Cassol and colleagues^[@bibr41-2049936119838228]^          Cross-sectional                 46 HIV and 54 HIV-negative controls                                                                                                                                                      CSF metabolites: neurotransmitters (glutamate, N-acetyl aspartate), markers of glial activation (myo-inositol), and ketone bodies (beta-hydroxybutyric acid, 1,2-propanediol)   NR in details                                              CSF metabolites correlated with worse neurocognitive test scores, plasma inflammatory biomarkers \[IFN-α, IFN-γ, (IL)-8, IL-1β, IL-6, IL-2Ra\], and intrathecal IFN responses                                                                                                                                                                                         8

  Merali and colleagues^[@bibr42-2049936119838228]^          Cross-sectional                 99 HIV (25 ANI, 25 MND, 25 HAND)                                                                                                                                                         CSF acetyl-polyamine                                                                                                                                                            NR in details                                              CSF levels of acetylated polyamine increase with the degree of HAND severity                                                                                                                                                                                                                                                                                          8

  Peterson^[@bibr43-2049936119838228]^                       Cross-sectional                 143 HIV-infected patients (PHI, 20 with CD4 \>350, 20 with CD4 200--349, 20 with CD4 50--199, 20 with CD4 \<50, 12 HAD, 19 treated- suppressed, 8 elites) and 20 HIV-negative controls   NFL + t-tau, p-tau + sAPPα, sAPPβ + Aβ 1-42, 1--40 and 1--38                                                                                                                    NA                                                         sAPPa and b were decreased in HAD, showed less marked change than NFL with CD4 decline in the absence of HAD, and were not decreased in PHI. The CSF Ab peptides and p-tau did not differ among the groups                                                                                                                                                            7

  Anderson and colleagues^[@bibr44-2049936119838228]^        Cross-sectional                 15 HAND                                                                                                                                                                                  CSF IFNα + NFL                                                                                                                                                                  Trail-making Part A;\                                      CSF IFNα levels correlate with HAND                                                                                                                                                                                                                                                                                                                                   8
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Trail-making Part B; Hopkins verbal learning test total\                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      recall;\                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Hopkins verbal learning test delayed recall;\                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      grooved pegboard (dominant hand);\                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Stroop color/word;\                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      letter fluency (controlled oral word association test);\                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      animal fluency.                                                                                                                                                                                                                                                                                                                                                                                                                  

  Gougeon and colleagues^[@bibr45-2049936119838228]^         Cross-sectional                 103 HIV-infected patients (73 no HAND, 30 HAND)                                                                                                                                          CSF + blood: 27 cytokines + chemokines, HMGB1 + anti-HMGB1 IgG autoantibodies                                                                                                   NA                                                         CSF HMGB1 levels were positively correlated with HIV-1 DNA in aviremic. HAND patients anti-HMGB1 IgG antibody levels could discriminate patients with no HAND from patients with no HAND and a single deficit                                                                                                                                                         7

  Sun and colleagues^[@bibr46-2049936119838228]^             Cross-sectional                 23 HIV-infected patients (11 undetectable HIV viral load (UD, \<40 copies/ml) and 12 with plasma HIV viral load at the time of blood draw) and 12 HIV-negative controls                  Plasma NDE HMGB1+ NF-L + Aβ proteins + NFL                                                                                                                                      NA                                                         Elevated HMGB1, NF-L and Aβ proteins could distinguish cognitive impairment.                                                                                                                                                                                                                                                                                          7
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANI, asymptomatic neurocognitive impairment; NP, neuropsychological; DAT, dementia of the Alzheimer type; MND, mild neurocognitive disorder; HAND, HIV-associated neurologic disorders; CSF, cerebrospinal fluid; IFN-α, interferon-α; IL, interleukin; Aβ42, β-amyloid(1-42); Aβ40, β-amyloid (1--40); t-tau, total tau; p-tau181, phosphorylated tau; NFL, neurofilament light chain; sAPPα and sAPPβ, soluble amyloid precursor proteins alpha and beta; HMGB1, high mobility group box 1; NDE, neuron-derived exosomes; PHI, 'primary' HIV infection; HAD, HIV-associated dementia; NA, not available.

Neuropathogenesis of HAND: inflammation, glutamate and glia as the trio of mess. A link between cART and HAND {#section9-2049936119838228}
=============================================================================================================

Since 2009, there has been a robust body of evidence identifying sustained inflammation in HAND as a critical pathogenic element. The main idea is that HIV replicates in the CNS, particularly in subcortical structures.^[@bibr47-2049936119838228]^ This specific anatomical region may explain the neuropsychological impairment pattern observed in HAND.^[@bibr48-2049936119838228]^ Since neurons have the lowest susceptibility to HIV infection among all cells of the CNS, their dysfunction likely results from infection of neighboring cells such as macrophages and microglia, which are cells with immune functions in the brain. Activated macrophages and microglia (Trojan horses) produce viral proteins (glycoprotein, gp-120, Tat protein and chemokines) that have the ability to damage the synapse. These proteins also activate uninfected astrocytes (a key cell supporting neurons) which will result in increased glutamate release.^[@bibr49-2049936119838228]^ Elevated extracellular glutamate levels lead to aberrant synaptodendritic pruning and neuronal injury. Overall, all these toxic molecules participate in a vicious cycle with overactivation of NMDA receptors and consequent excitotoxicity, free radical formation, TNF-α, arachidonic acid, quinolinic acid and nitric oxide, resulting in glial activation and neurodegeneration. Other risk factors such as methamphetamine use, coinfection with hepatitis C and atherosclerosis contribute to HAND, through further activation of uninfected macrophages and microglial cells. Despite inflammation as a key feature of HAND, its presence in the CNS is not the sine qua non for active HIV viral replication.^[@bibr50-2049936119838228]^ So far, neuro inflammation continues to be the core of intense study, because inhibiting viral replication alone has delayed, but not stopped HAND progression.

The integrase strand transfer inhibitors (INSTIs) raltegravir, dolutegravir and elvitegravir are used as first-line ART in a combination of two nucleosides \[nucleoside reverse transcriptase inhibitors (NRTIs) and either a nonnucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI)\].^[@bibr51-2049936119838228]^ These drugs may decrease the severity of neuropathogenesis but cannot prevent the emergence of milder forms of HAND. Older NRTIs (zidovudine and abacavir) are associated with a reduced incidence of HAD, which is likely attributed to effective CNS penetration.^[@bibr51-2049936119838228]^ A CNS penetration-effectiveness (CPE) index recently has been proposed to guide the choice of antiretrovirals in patients with HAND. Each antiretroviral drug is given a score of 1 to 4 (4 = much above average CNS penetration, 3 = above average, 2 = average, 1 = below average), and the sum of the individual agents' scores in a combination regimen provides the CPE score for that regimen. Individual ART agents with scores of 4 include zidovudine, nevirapine, and indinavir/ritonavir. Notably, a combination of NRTI and NNRTI with good CNS penetration was associated with a poorer neurocognitive performance.^[@bibr16-2049936119838228],[@bibr20-2049936119838228]^ Previous studies have yielded conflicting results on the effect of cART on cognition^[@bibr14-2049936119838228],[@bibr15-2049936119838228],[@bibr18-2049936119838228],[@bibr19-2049936119838228],[@bibr22-2049936119838228],[@bibr12-2049936119838228],[@bibr13-2049936119838228],[@bibr17-2049936119838228]^ ([Table 1](#table1-2049936119838228){ref-type="table"}). An explanation might be that the reduction of neural stem cell proliferation due to NRTIs could contribute to a decline in the regenerative actions of these cells, which under NNRTI conditions would oppose the chronic injury induced in the brain by HIV itself, HIV-activated glial cells, or HIV-secreted proteins such as gp120 and Tat.

Adjuvant therapies for HAND: what is new in an old story {#section10-2049936119838228}
========================================================

Since the introduction of cART in 1996, 11 adjuvant therapies (as mitigates of pathogenesis) have been studied as following: (1) memantine, as a first generation NMDA receptor antagonist showed no cognitive improvement in HAND patients,^[@bibr30-2049936119838228]^ (2) selegiline a monoamine oxidase B inhibitor produced no significant benefit,^[@bibr17-2049936119838228]^ (3) deprenyl with cognitive improvement + thioctic acid (α-lipoic acid) without significant benefit,^[@bibr24-2049936119838228]^ (4) valproic acid (HDAC inhibitor, GABAergic effects)^[@bibr28-2049936119838228]^ with benefit, (5) lithium (unknown mechanism)^[@bibr31-2049936119838228]^ without benefit, (6) CPI-1189 (TNFα blocker)^[@bibr27-2049936119838228]^ without benefit, (7) peptide T (blocks gp120 binding to brain tissue)^[@bibr25-2049936119838228]^ with improvement in patients with NP global deficit score ⩾0.5 or with relatively preserved immunological status (CD4 count \> 0.200 109 cells/L,(8) lexipafant (platelet-activating factor receptor antagonist)^[@bibr26-2049936119838228]^ with trends toward improvement, (9) OPC-14117 (free radical scavenger)^[@bibr23-2049936119838228]^ without benefit, (10) rivastigmine (acetylcholinesterase inhibitor)^[@bibr33-2049936119838228]^ without benefit, and (11) minocycline (tetracycline-class antibiotic) without benefit^[@bibr32-2049936119838228]^ ([Table 2](#table2-2049936119838228){ref-type="table"}). These studies gave mixed results (seven negative *versus* four positive).

However, research efforts need a long way before gaining positive results in patients with HAND. Specifically, nitro memantine, a second-generation NMDA receptor antagonist that preserved synaptic normal activity, which suggested a better tolerability while allowing the use of higher and more effective doses.^[@bibr52-2049936119838228],[@bibr53-2049936119838228]^ A combination of erythropoietin and insulin growth factor 1, two United States Food and Drug Administration (US FDA)-approved biological agents for other indications, showed a remarkable neuroprotection, in part, in a mouse model of HAND, through cooperative activation of phosphatidylinositol 3-kinase/Akt/GSK-3β signaling. Nonetheless, it still remains to be tested in humans with HAND.^[@bibr54-2049936119838228]^

Furthermore, statins HMG-CoA reductase inhibitors, have gained interest due to *in vitro* evidence of modulation of the immune system, and possibly of HIV replication.^[@bibr55-2049936119838228]^ However, there was no significant effect of atorvastatin on levels of CSF HIV RNA and neurocognitive performance.^[@bibr55-2049936119838228]^

Given that serotonin (5-hydroxytryptamine) and its receptors may play a role in HIV replication and disease progression, there has been growing interest in selective serotonin reuptake inhibitors (SSRIs, e.g. citalopram, sertraline, trazodone) as HIV infectivity modulators. While controlled studies are lacking, a cross-sectional study of 658 HIV patients with cognitive impairment has shown better neurocognitive performance as well as undetectable CSF HIV RNA with SSRIs, but not with statins.^[@bibr34-2049936119838228]^

Future directions of HAND pharmacotherapy research {#section11-2049936119838228}
==================================================

One of the barriers of novel HAND pharmacotherapy is the lack of interest from the pharmaceutical industry in the development of therapeutics for HAND, because the condition has not been perceived as an applicable target. This condition translates into enormous costs for the academic sector to insist on new therapeutics for HAND. An example of ongoing efforts is the development of intranasal insulin, or cambinol (sphingomyelinase inhibitor), as therapeutic agents for ANI and MND.^[@bibr56-2049936119838228]^ Intervening with drugs targeting astroglia may disrupt the neuroinflammation during HIV-1 infection and methamphetamine abuse. These drugs may be multiple sclerosis drugs, such as fingolimod,^[@bibr57-2049936119838228]^ copolymer-1,^[@bibr58-2049936119838228]^ antioxidants, such as flavonoids,^[@bibr59-2049936119838228]^ and synthetic cannabinoids.^[@bibr60-2049936119838228],[@bibr61-2049936119838228]^ HIV-associated comorbidities, neurological and metabolic complications and related glia implications will continue to constitute the hotspot of future research. So far, it is unknown how these interactions differ in the setting of long-term cART. Epigenetic factors may play a significant role in those interactions, but we have only seen the tip of the iceberg in terms of genetic susceptibility in future HAND pharmacogenomic research.

Immune and neuronal biomarkers {#section12-2049936119838228}
==============================

In 1998, the National Institutes of Health Biomarkers Definitions Working Group defined a biomarker as 'a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.'^[@bibr62-2049936119838228]^ In the new era of cART, both CSF and blood biomarkers of viral load, immune/inflammatory responses or neuronal injury are less likely to discriminate among the milder HAND subtypes. Elevated levels of sCD40L and TNF-α in CSF and plasma have been reported as a general marker for HAND.^[@bibr35-2049936119838228]^ CCR2 on CD14+CD16+ monocytes were not associated to HIV disease progression or severity of HAND.^[@bibr40-2049936119838228]^ Alterations in the CSF metabolome of HIV patients on cART overlapped with advanced age in HIV-negative controls.^[@bibr41-2049936119838228]^ CSF levels of acetylated polyamine increase with the degree of HAND severity.^[@bibr42-2049936119838228]^ Elevated sCD163 in plasma but not CSF is a marker of neurocognitive impairment in HIV infection.^[@bibr39-2049936119838228]^ Although nonspecific, elevated levels of CSF neopterin (marker for monocytes, macrophages, microglia, and astrocytes) are associated with an increased risk of dementia.^[@bibr37-2049936119838228]^ Low CSF leptin levels are associated with worse learning and memory performance in HIV-infected men.^[@bibr37-2049936119838228]^ CSF interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-infected individuals.^[@bibr44-2049936119838228]^ One of the promising neuronal biomarkers for dementia research, CSF Aβ42 levels \[metabolized product of soluble amyloid precursor proteins (sAPPs)\] were lower in HAND patients in respect to HIV + nondemented patients.^[@bibr36-2049936119838228]^ Increased CSF t-tau in HAND patients without a concomitant p-tau increase was reported as an indicator of neural injury without preferential accumulation of hyperphosphorylated tau as found in Alzheimer's disease (AD).^[@bibr43-2049936119838228]^ Other neuronal CSF biomarkers, such as neurofilament light protein (NFL) showed a different profile in AD compared with HAND, (reduced sAPP levels and increased NFL levels in HAND).^[@bibr45-2049936119838228]^ Of the above CSF neuronal biomarkers, NFL was the most sensitive and demonstrated the presence of active neural damage in early HAD stage.^[@bibr46-2049936119838228]^ High mobility group box 1 (HMGB1), a proinflammatory mediator, was elevated in the CSF of HIV patients on stable cART, as a biomarker for early stages of HAND.^[@bibr63-2049936119838228]^ NDE from HAND patients had significantly higher levels of HMGB1, NF-L and Aβ proteins compared with HIV-negative controls.^[@bibr64-2049936119838228]^ Elevated HMGB1, NF-L and Aβ proteins could distinguish among the early stages of HAND. The combined view of these fluid biomarkers suggested a novel profile and evolution of neuronal injury across viral suppression.

Discussion {#section13-2049936119838228}
==========

HAND remains an unresolved multifactorial problem in HIV patients under modern cART era that often achieves HIV suppression of replication to levels below the limit of detection of currently used assays. This review showed that no clinical trials of HAND therapies are effective beyond optimal suppression of HIV replication in the CNS.

An important finding of this review is the lack of definitive 'adjuvant' strategies. Significant methodological issues such as their cross-sectional nature do not permit causality.^[@bibr56-2049936119838228]^ However, an accurate longitudinal design is often impractical due to the prolonged period of HAND progression. In the same context, there is an absence of uniform access concerning neurocognitive assessment, likely related to multiple factors, including complex social situations, limited access to medical care and lack of concern in the HIV community as regards the long-term effects of HAND. For all these reasons, adjuvant HAND therapy would subsequently be tested in larger, and more rigorous confirmatory trials including multiple outcome measures such as neuropsychological scores, alterations of biomarkers or neuroimaging.^[@bibr65-2049936119838228]^

cART intensification involves extension of the traditional three-drug regimen to reduce inflammation caused by HIV and residual HIV viral replication, and hence the size of HIV latent reservoirs. There are conflicting data indicating whether intensifying cART will be necessary in cure strategies or not.^[@bibr64-2049936119838228][@bibr70-2049936119838228][@bibr71-2049936119838228][@bibr72-2049936119838228]--[@bibr68-2049936119838228]^ Despite the coexistence of multiple sites of HIV reservoirs (lymphoid tissue, bone marrow) it is important not to ignore the CNS as a major reservoir site for eradication strategies. The key idea is to accomplish a 'clean' and 'pure' CNS for a successful HIV eradication strategy. A potential factor limiting the efficacy of ARVs in the CNS is the blood--CNS barrier. Ideally, high ARV penetration into the CNS in therapeutic concentrations may reduce HIV RNA levels in the CSF, and perhaps better neurocognitive performance.^[@bibr69-2049936119838228]^ ARV drug susceptibility, besides drug CNS penetration, can play a role in the control of HAND.^[@bibr70-2049936119838228]^ Further adding to the complexity is the presence of transporters at the blood--CNS barrier that actively pump out drugs, including many ARVs currently in use. Detecting latent viral reservoirs could be another step, but the degree of this elimination cannot be estimated.^[@bibr71-2049936119838228]^ In addition, latency reversing agents might pose a risk of inflammatory over-response by activating latent viral reservoirs in the brain in immunocompetent patients with further neurological damage.

A crucial step is to quantify the penetration of various ARV drug regimens with emphasis on the CSF as a reflection of disease progression in CNS. Observational studies, rather than longitudinal, on reductions in the CSF viral load as a function of the resulting CPE have yielded controversies and no correlation with the development of HAND is proven.^[@bibr72-2049936119838228]^ The range to which ARV distribution and CNS toxicity influence clinical outcomes is also questionable. Dolutegravir (DTG), a once-daily, HIV type 1 (HIV-1) integrase inhibitor, achieved therapeutic concentrations in the CNS of cART-naïve patients.^[@bibr73-2049936119838228]^ In contrast, in a large cohort of 1938 HIV cART-naïve patients at enrollment, 74% of those receiving cART with high CPE showed an increased risk of HAND. A practical guide suggests the use of the most tolerable cART regimen, without taking into account nonverifiable CPE in order to avoid confusion.

There is a matter of involvement of poor neurocognitive function under cART and neurotoxicity of these drugs, leading to persistence of HAND.^[@bibr74-2049936119838228]^ One *in vitro* study, using markers for neuronal damage (MAP-2 staining, dendritic arborization complexity, and neural responses to exogenous calcium) showed neuronal toxicity of 15 different antiretroviral drugs from different drug classes.^[@bibr75-2049936119838228]^ For example, long term use of efavirenz, a common cART, was correlated with worse neurocognitive functioning compare to lopinavir-ritonavir, suggesting an antiretroviral neurotoxicity.^[@bibr21-2049936119838228]^ However, drug--disease interactions, such as hepatitis C virus coinfection, are still too complex to be explained. The clinical relevance of these findings for other cART regimens remains uncertain. The question is whether the benefits of better HIV suppression through greater penetration of antiretrovirals in the CNS may be balanced by neurotoxicity. Even the large and prospective HIV Anti-Retroviral Therapy Effects Research (CHARTER) study was unable to demonstrate cART effects.^[@bibr76-2049936119838228]^ Early introduction of cART with strict monitoring assure sustenance of viral suppression and immune-competence, leading to favorable neurocognitive effects.^[@bibr77-2049936119838228]^ For the past two decades, cART has been an indisputable life-saving regimen, and hence should not be discontinued, despite the theoretically complex issue of neurotoxicity.

One of the strengths of this review is to reveal the absence of sensitive and highly specific markers of HAND subtypes prediction/or progression in previous studies.^[@bibr34-2049936119838228],[@bibr35-2049936119838228],[@bibr56-2049936119838228],[@bibr57-2049936119838228][@bibr61-2049936119838228][@bibr62-2049936119838228][@bibr63-2049936119838228][@bibr64-2049936119838228]--[@bibr62-2049936119838228]^ A potential explanation might be the lower levels of immune activation in HIV patients with prolonged viral suppression on cART. There may be other non-inflammatory mechanisms, such as cerebrovascular dysfunction, metabolic modifications, or neurotoxicity of cART regimens, but their relationship with HAND subtypes remains elusive. However, a promising finding of this review is that the combination of fluid neuronal biomarkers could distinguish among early stages of HAND^[@bibr55-2049936119838228]^ and further predict a positive outcome of cART.

There are various limitations of the included studies. First, numerous methodological issues were identified in many of the studies such as poor study design (e.g. cross-sectional). Future research should include longitudinal studies with important information on how individual differences impact long-term treatment outcomes. Second, there are various confounding conditions in included studies such as demographics (e.g. age, race, sex), comorbidities (HCV coinfection, smoking, alcohol.^[@bibr14-2049936119838228][@bibr15-2049936119838228]--[@bibr16-2049936119838228],[@bibr18-2049936119838228][@bibr19-2049936119838228]--[@bibr20-2049936119838228],[@bibr22-2049936119838228],[@bibr30-2049936119838228],[@bibr12-2049936119838228],[@bibr13-2049936119838228],[@bibr17-2049936119838228]^ Third, there is an important heterogeneity of HIV cohorts (e.g. current and nadir CD4 count, initiation of cART, previous and current cART regimens), which make difficult to establish a clear causal link between treatment and outcome.^[@bibr14-2049936119838228][@bibr15-2049936119838228]--[@bibr16-2049936119838228],[@bibr18-2049936119838228][@bibr19-2049936119838228]--[@bibr20-2049936119838228],[@bibr22-2049936119838228],[@bibr30-2049936119838228],[@bibr12-2049936119838228],[@bibr13-2049936119838228],[@bibr17-2049936119838228]^ Another issue regarding cART monitoring using biomarkers is the heterogeneity of techniques; for example, current standard enzyme-linked immunosorbent assay methods are insensitive to very low concentrations of biomarkers in CSF and blood. However, major differences existed for (1) type of antibodies, (2) type of calibrators to build the standard curve, and (3) detection/quantitation methods. Future studies should include monitoring with standard methods for biomarkers employed in drug discovery for HAND.

However, this review is not without its limitations. There are a small number of studies available for analysis. We searched a limited number of databases. Consequently, there is always the possibility that we overlooked studies in other databases. In addition, there is always the possibility of publication bias due to underreported negative results and grey literature. However, the use of fewer search limits increases the sensitivity of the search method.

Relevance to patient care and clinical practice {#section14-2049936119838228}
===============================================

An accurate phenotyping of HIV patients, incorporating an array of markers relevant to HAND pathophysiology, may assess the individual's risk and potential response to personalized antiretroviral treatment.

Conclusion {#section15-2049936119838228}
==========

So far, optimal pharmacotherapy of HAND does not exist. HAND is not a rare complication in HIV patients under cART. HAND management remains an under-researched clinical entity with many unanswered questions regarding its epidemiology, pathophysiology and treatment. The wide range of adjuvant therapies that have been studied for HAND management show that we are still in an exploratory phase regarding its treatment. This review provides foundation for future studies using standardized procedures to confirm previous findings and expand on speculations as to whether a combination of biomarkers can increase discriminating power. There is a lack of highly specific markers to distinguish HAND subtypes or predict the disease's progression. A combination of validated surrogate markers should be used to distinguish between milder HAND subtypes and improve efficiency of clinical trials, after strict control of confounders.
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